Sarojini Nadimpally: Addressing Maternal Health Inequities in Sickle Cell Disease
Sarojini Nadimpally, The Chief Functionary at SAMA, shared Sama Resource Group for Women and Health‘s post on LinkedIn, adding:
“Pregnancy with Sickle Cell Disease (SCD) is about far more than pain crises and anaemia. It is also about the structural determinants that shape whether a woman can access timely, respectful, and appropriate maternal healthcare.
For Adivasi communities, who are disproportionately affected by SCD in India, these inequities are even more pronounced. Barriers related to geography, poverty, stigma, gender, and gaps in health systems profoundly influence pregnancy outcomes and experiences of care.
The latest desk review of the studies in India by the Sama Resource Group for Women and Health brings together the existing evidence on SCD and maternal health in India.”
Sama Resource Group for Women and Health shared a post on LinkedIn:
“For women living with Sickle cell disease (SCD), maternal health isn’t just about prenatal check-ups; it’s about pain crises, anaemia, and a heightened risk of complications that mainstream maternal care too often overlooks.
But the story doesn’t end at clinical risk. SCD impacts broader socioeconomic reproductive outcomes, including maternal mortality. It’s shaped by structural determinants: where a woman lives, what she can afford, and how far she must travel for health care.
It’s also shaped by nutrition, often compromised long before pregnancy begins and by the quiet, unaddressed weight of anxiety and mental health struggles that accompany carrying a pregnancy while managing a chronic illness.
And for many women in India’s Adivasi and other marginalised communities, all of this is compounded by systemic neglect and limited access to informed, sickle-cell-related care.
Despite India’s progress in maternal health, providing equitable care for women with sickle cell disease (SCD) remains challenging.
At Sama Resource Group for Women and Health, we believe it’s time SCD found its rightful place in the maternal health discourse, not as a footnote, but as a policy priority.”
Stay updated with Hemostasis Today.
-
Nov 15, 2026, 10:32Ibrahim Gwarzo: Identifying Care Gaps and Emergency Pain Delays in Sickle Cell Disease at APHA 2026
-
Nov 15, 2026, 10:17Ify Osunkwo: How the Sickle Cell Community Can Influence FDA Drug Development Priorities
-
Nov 15, 2026, 10:11Ahmed Abdelsalam: Why Matching ABO and RhD Groups Does Not Guarantee Crossmatch Compatibility
-
Nov 15, 2026, 10:06Asma Khalil: New British Society for Haematology Guidance on Paediatric and Neonatal Transfusion
-
Nov 15, 2026, 09:41Girishkumar Modi: Navigating the 2026 Jehovah’s Witness Transfusion Policy Shift in Clinical Practice
-
Nov 15, 2026, 04:31Aakriti Gupta: Anticoagulation for Leaflet Thickening After TAVR
-
Nov 14, 2026, 23:57Jamie S. Y. Ho: Exploring the Mechanisms of Arterial Thrombosis and the Evolution of Antithrombotic Therapy
-
Nov 14, 2026, 23:53Jacopo Imberti: The Past, Present and Future of Arterial Thrombosis Research
-
Nov 14, 2026, 23:48Shrouk Ramadan: Joining the Editorial Review Board of Clinical and Applied Thrombosis and Hemostasis